Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $89.90 Consensus PT from Analysts

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have been given a consensus recommendation of “Buy” by the twelve brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, ten have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $89.90.

JANX has been the subject of several analyst reports. BTIG Research increased their price target on shares of Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. UBS Group began coverage on Janux Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $69.00 price objective for the company. Leerink Partnrs upgraded Janux Therapeutics to a “strong-buy” rating in a research report on Friday, November 22nd. Leerink Partners increased their price target on Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a report on Tuesday, December 3rd. Finally, HC Wainwright boosted their price objective on shares of Janux Therapeutics from $63.00 to $70.00 and gave the company a “buy” rating in a report on Tuesday, December 3rd.

Janux Therapeutics Stock Performance

NASDAQ JANX opened at $56.75 on Friday. The stock’s fifty day moving average is $53.89 and its two-hundred day moving average is $47.05. The firm has a market capitalization of $2.98 billion, a P/E ratio of -48.50 and a beta of 3.29. Janux Therapeutics has a fifty-two week low of $7.79 and a fifty-two week high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The firm had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics’s revenue for the quarter was down 82.6% on a year-over-year basis. As a group, sell-side analysts forecast that Janux Therapeutics will post -1.35 EPS for the current year.

Insider Buying and Selling at Janux Therapeutics

In related news, Director Ra Capital Management, L.P. purchased 1,200,000 shares of Janux Therapeutics stock in a transaction on Friday, October 18th. The shares were bought at an average price of $44.75 per share, with a total value of $53,700,000.00. Following the transaction, the director now directly owns 9,317,246 shares of the company’s stock, valued at approximately $416,946,758.50. This trade represents a 14.78 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO David Alan Campbell sold 15,000 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $67.00, for a total value of $1,005,000.00. Following the transaction, the chief executive officer now directly owns 242,054 shares of the company’s stock, valued at approximately $16,217,618. This represents a 5.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 192,032 shares of company stock valued at $9,512,515 in the last three months. 29.40% of the stock is owned by corporate insiders.

Institutional Trading of Janux Therapeutics

Several hedge funds have recently added to or reduced their stakes in JANX. Charles Schwab Investment Management Inc. increased its position in shares of Janux Therapeutics by 202.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock valued at $10,639,000 after purchasing an additional 156,675 shares during the last quarter. Ally Bridge Group NY LLC acquired a new position in shares of Janux Therapeutics during the third quarter worth $4,943,000. Algert Global LLC purchased a new position in Janux Therapeutics in the third quarter valued at $1,112,000. FMR LLC raised its stake in Janux Therapeutics by 0.6% in the third quarter. FMR LLC now owns 7,824,675 shares of the company’s stock valued at $355,475,000 after buying an additional 47,075 shares in the last quarter. Finally, Neo Ivy Capital Management purchased a new stake in Janux Therapeutics during the 3rd quarter worth about $940,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.